Progesterone for Hot Flashes in Menopausal Women
Progesterone alone is effective for treating hot flashes in menopausal women who cannot tolerate estrogen therapy, but estrogen-based therapy remains the first-line treatment for vasomotor symptoms. For women with a uterus taking estrogen, progesterone is mandatory to prevent endometrial hyperplasia and cancer, not optional 1.
Treatment Algorithm Based on Uterine Status
Women WITHOUT a Uterus
- Use estrogen alone for hot flashes—progesterone adds no benefit and only increases side effects
- Estrogen reduces hot flash frequency by approximately 75% 2
- No need for progesterone since there's no endometrium to protect
Women WITH a Uterus
If tolerating estrogen:
- Combined estrogen-progesterone therapy is required 1
- Progesterone dose: 200 mg oral micronized progesterone at bedtime for 12 continuous days per 28-day cycle 3
- This combination prevents endometrial hyperplasia (6% incidence vs 64% with estrogen alone) 3
- The progesterone component is for endometrial protection, not hot flash treatment
If estrogen is contraindicated or not tolerated:
- Progesterone monotherapy is a reasonable alternative 1
- Dose: 300-400 mg oral micronized progesterone at bedtime 4
- Reduces hot flashes by approximately 55-58% (vs 23.5% placebo) 5, 4
- Less effective than estrogen (75% reduction) but superior to placebo 2
Evidence Quality and Nuances
The strongest evidence comes from the 2015 Endocrine Society Clinical Practice Guideline 1, which explicitly states: "For those who do not tolerate ET, progestogens can relieve VMS. In RCTs, oral synthetic progestogens and micronized progesterone were effective."
The pivotal RCT by Prior et al. (2012) 4 demonstrated that 300 mg oral micronized progesterone reduced hot flash scores significantly more than placebo in 133 healthy postmenopausal women over 12 weeks. A systematic review 5 confirmed these findings but noted heterogeneity in formulations and doses across studies.
Critical distinction: Depot medroxyprogesterone acetate (MPA) injections show even higher efficacy (79-90% reduction) 6, 7, but this is a different formulation than oral micronized progesterone.
Important Caveats
- Take progesterone at bedtime due to drowsiness, dizziness, and potential sedation 3
- Contains peanut oil—contraindicated in peanut allergy 3
- Side effects include headache (31%), breast tenderness (27%), dizziness (15%), and vaginal bleeding 3
- Discontinuation rates due to adverse events: 6-21% 5
- Avoid in breast cancer patients—effect on recurrence is unclear 1
Practical Prescribing
For progesterone monotherapy:
- Start with 300 mg oral micronized progesterone at bedtime 4
- Can increase to 400 mg if inadequate response 5
- Take with water while standing to prevent dysphagia 3
- Expect 55-60% reduction in hot flashes within 12 weeks 5, 4
- Monitor for excessive sedation, especially in first few weeks
Use only FDA-approved formulations—avoid custom-compounded progesterone due to lack of quality control and unproven endometrial protection 1.